Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients

Annals of Surgical Oncology

Volumn 19, Issue 2, 2012, Pages 519-526

  Fitzal, Florian ^a   Mittlboeck, Martina ^a   Steger, Guenther ^a   Bartsch, Rupert ^a   Rudas, Margaretha ^a   Dubsky, Peter ^a   Riedl, Otto ^a   Jakesz, Raimund ^a   Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; BREAST CONSERVATION THERAPY; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONTROLLED STUDY; EMBOLISM; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MASTECTOMY; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856669831     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1879-9     Document Type: Article

References (27)

1. M Kaufmann G von Minckwitz R Smith, et al. 2003 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2600 2608 12829681 10.1200/JCO.2003.01.136
2. H Charfare S Limongelli AD Purushotham 2005 Neoadjuvant chemotherapy in breast cancer Br J Surg 92 14 23 15635596 10.1002/bjs.4840 1:STN:280: DC%2BD2M%2Fhs1egsg%3D%3D
3. RL Jones IE Smith 2006 Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response Lancet Oncol 7 869 874 17012049 10.1016/S1470-2045(06)70906-8 1:CAS:528:DC%2BD28XhtVantb3M
4. JS Mieog JA van der Hage CJ van de Velde 2007 Neoadjuvant chemotherapy for operable breast cancer Br J Surg 94 1189 1200 17701939 10.1002/bjs.5894 1:STN:280:DC%2BD2srmslaktA%3D%3D
5. GM Kiebert JC de Haes CJ van de Velde 1991 The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review J Clin Oncol 9 1059 1070 2033420 1:STN:280:DyaK3M3jsleqsA%3D%3D
6. D Mauri N Pavlidis JP Ioannidis 2005 Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 188 194 15687361 10.1093/jnci/dji021
7. Steger GG, Greil R, Jakesz R, et al. A randomized phase III study comparing epirubicin, doxetacel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer-first results of the ABCSG Trial 24. Annual Meeting of the European Society of Medical Oncology. 2009.
8. A Purushotham S Pinder M Cariati M Harries A Goldhirsch 2010 Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 28 3552 3554 20606095 10.1200/JCO.2009.27.8184
9. A Katz ED Saad P Porter L Pusztai 2007 Primary systemic chemotherapy of invasive lobular carcinoma of the breast Lancet Oncol 8 55 62 17196511 10.1016/S1470-2045(06)71011-7 1:CAS:528:DC%2BD2sXhsFGlsw%3D%3D
10. G Soucy J Belanger G Leblanc, et al. 2008 Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact? J Am Coll Surg 206 1116 1121 18501808 10.1016/j.jamcollsurg.2007.12.025
11. JC Boughey J Wagner BJ Garrett, et al. 2009 Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation Ann Surg Oncol 16 1606 1611 19280264 10.1245/s10434-009-0402-z
12. G Steger E Kubista H Hausmaninger, et al. 2004 6 vs. 3 Cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14 J Clin Oncol 22 553
13. S Taucher GG Steger R Jakesz, et al. 2008 The potential risk of neoadjuvant chemotherapy in breast cancer patients-results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07) Breast Cancer Res Treat 112 309 316 18080748 10.1007/s10549-007-9844- 9 1:CAS:528:DC%2BD1cXht1Cms73K
14. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;96-102.
15. O Riedl F Fitzal N Mader, et al. 2009 Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer Eur J Surg Oncol 35 264 270 18706785 10.1016/j.ejso.2008.05.007 1:STN:280: DC%2BD1M7jslSitQ%3D%3D
16. S Loibl G von Minckwitz G Raab, et al. 2006 Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial Ann Surg Oncol 13 1434 1442 16983592 10.1245/s10434-006-9011-2
17. A Reiner B Neumeister J Spona G Reiner M Schemper R Jakesz 1990 Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer Cancer Res 50 7057 7061 2208173 1:STN:280:DyaK3M%2FgsVSrtg%3D%3D
18. F Fitzal O Riedl L Wutzl, et al. 2007 Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients Breast Cancer Res Treat 103 45 52 17417725 10.1007/s10549-006-9325-6
19. ME Straver EJ Rutgers S Rodenhuis, et al. 2010 The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy Ann Surg Oncol 17 2411 2418 20373039 10.1245/s10434-010-1008-1 1:STN:280:DC%2BC3cjmtVCqsQ%3D%3D
20. MC Mathieu R Rouzier A Llombart-Cussac, et al. 2004 The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile Eur J Cancer 40 342 351 14746851 10.1016/j.ejca.2003.08.015
21. LA Newman AU Buzdar SE Singletary, et al. 2002 A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility Ann Surg Oncol 9 228 234 11923128 10.1007/BF02573059
22. VF Cocquyt PN Blondeel HT Depypere, et al. 2003 Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma Eur J Surg Oncol 29 361 367 12711290 10.1053/ejso.2002.1404 1:STN:280:DC%2BD3s7pt1eisA%3D%3D
23. J Wagner JC Boughey B Garrett, et al. 2009 Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer Am J Surg 198 387 391 19362281 10.1016/j.amjsurg.2009.01.006
24. M Cristofanilli A Gonzalez-Angulo N Sneige, et al. 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 41 48 15625359 10.1200/JCO.2005.03.111
25. B Fisher J Bryant N Wolmark, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 9704717 1:CAS:528:DyaK1cXlsFCgurg%3D
26. M Tubiana-Hulin D Stevens S Lasry, et al. 2006 Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution Ann Oncol 17 1228 1233 16740599 10.1093/annonc/mdl114 1:STN:280:DC%2BD28vkvVOrsA%3D%3D
27. VF Semiglazov VV Semiglazov GA Dashyan, et al. 2007 Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 244 254 17538978 10.1002/cncr.22789 1:CAS:528:DC%2BD2sXos1yrsbk%3D